Top

Published in:

01-06-2008 | Original Investigation

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

Authors: Véronique Mersseman, Verena Böhm, Rafaela Holtappels, Petra Deegen, Uwe Wolfrum, Bodo Plachter, Sabine Reyda

Published in: Medical Microbiology and Immunology | Issue 2/2008

Abstract

Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now. Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined. Analysis of viral mutants that were constructed in this process provided the proof-of-principle that heterologous antigens can be packaged into recDB and that these particles prime CD8 T cell responses against the recombinant antigen upon their application to HLA-A2 transgenic mice.

Hebart H, Einsele H (2004) Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65:432–436PubMedCrossRef

Fowler KB, Boppana SB (2006) Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 35:226–231PubMedCrossRef

Mocarski ES, Shenk T, Pass RF (2007) Cytomegaloviruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 2701–2772

van der Sande MA, Kaye S, Miles DJ, Waight P, Jeffries DJ, Ojuola OO, Palmero M, Pinder M, Ismaili J, Flanagan KL, Aveika AA, Zaman A, Rowland-Jones S, McConkey SJ, Whittle HC, Marchant A (2007) Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS ONE 2:e492PubMedPubMedCentralCrossRef

Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–3108PubMedPubMedCentralCrossRef

Steffens HP, Kurz S, Holtappels R, Reddehase MJ (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 72:1797–1804PubMedPubMedCentralCrossRef

Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044PubMedCrossRef

Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G, Hebart H (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922PubMedCrossRef

Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362:1375–1377PubMedCrossRef

10.

Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386PubMedPubMedCentralCrossRef

11.

Moss P, Rickinson A (2005) Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol 5:9–20PubMedCrossRef

12.

Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, Brookes P, de la FJ, Kanfer E, Apperley JF, Goldman JM (2001) Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 112:228–236PubMedCrossRef

13.

Wehler TC, Nonn M, Brandt B, Britten CM, Grone M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig UF, Herr W (2007) Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109:365–373PubMedCrossRef

14.

Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W (2008) Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 14:99–109PubMedCrossRef

15.

Pahl-Seibert MF, Jülch M, Podlech J, Thomas D, Deegen P, Reddehase MJ, Holtappels R (2005) Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 79:5400–5413PubMedPubMedCentralCrossRef

16.

Holtappels R, Podlech J, Pahl-Seibert MF, Jülch M, Thomas D, Simon CO, Wagner M, Reddehase MJ (2004) Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med 199:131–136PubMedPubMedCentralCrossRef

17.

Khanna R, Diamond DJ (2006) Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26–33PubMedCrossRef

18.

Schleiss MR, Heineman TC (2005) Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381–406PubMedCrossRef

19.

Pepperl-Klindworth S, Plachter B (2006) Current perspectives in vaccine development. In: Reddehase MJ (eds) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press Ltd, Wymondham

20.

Zhong J, Khanna R (2007) Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 5:449–459PubMedCrossRef

21.

Pepperl S, Münster J, Mach M, Harris JR, Plachter B (2000) Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 74:6132–6146PubMedPubMedCentralCrossRef

22.

Pepperl-Klindworth S, Frankenberg N, Plachter B (2002) Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol 25 (Suppl 2):S75–S85PubMedCrossRef

23.

Beninga J, Kropff B, Mach M (1995) Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol 76:153–160PubMedCrossRef

24.

Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569–7579PubMedPubMedCentralCrossRef

25.

McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103–110PubMedCrossRef

26.

Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG (1988) Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168:919–931PubMedCrossRef

27.

Kern F, Surel IP, Faulhaber N, Frömmel C, Schneider-Mergener J, Schonemann C, Reinke P, Volk HD (1999) Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73:8179–8184PubMedPubMedCentralCrossRef

28.

Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:1031–1036PubMedPubMedCentralCrossRef

29.

Lacey SF, La RC, Zhou W, Sharma MC, Martinez J, Krishnan A, Gallez-Hawkins G, Thao L, Longmate J, Spielberger R, Forman SJ, Limaye A, Zaia JA, Diamond DJ (2006) Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 194:1410–1421PubMedCrossRef

30.

Simon CO, Holtappels R, Tervo HM, Böhm V, Däubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, Reddehase MJ, Grzimek NKA (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436–10456PubMedPubMedCentralCrossRef

31.

Pepperl-Klindworth S, Frankenberg N, Riegler S, Plachter B (2003) Protein delivery by subviral particles of human cytomegalovirus. Gene Ther 10:278–284PubMedCrossRef

32.

Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH (1997) Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci USA 94:14759–14763PubMedPubMedCentralCrossRef

33.

Borst EM, Hahn G, Koszinowski UH, Messerle M (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73:8320–8329PubMedPubMedCentralCrossRef

34.

Lee EC, Yu D, Martinez d V, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG (2001) A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73:56–65PubMedCrossRef

35.

Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33:e36PubMedPubMedCentralCrossRef

36.

Mach M, Kropff B, Kryzaniak M, Britt W (2005) Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 79:2160–2170PubMedPubMedCentralCrossRef

37.

Greenaway PJ, Oram JD, Downing RG, Patel K (1982) Human cytomegalovirus DNA: BamHI, EcoRI and PstI restriction endonuclease cleavage maps. Gene 18:355–360PubMedCrossRef

38.

Gallez-Hawkins G, Villacres MC, Li X, Sanborn MC, Lomeli NA, Zaia JA (2003) Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol 77:4457–4462PubMedPubMedCentralCrossRef

39.

Retiere C, Prod’homme V, Imbert-Marcille BM, Bonneville M, Vie H, Hallet MM (2000) Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J Virol 74:3948–3952PubMedPubMedCentralCrossRef

40.

Prod’homme V, Retiere C, Imbert-Marcille BM, Bonneville M, Hallet MM (2003) Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315–324) epitope of human cytomegalovirus. J Immunol 170:2030–2036PubMedCrossRef

41.

Frankenberg N, Pepperl-Klindworth S, Meyer RG, Plachter B (2002) Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology 295:208–216PubMedCrossRef

42.

Rüger B, Klages S, Walla B, Albrecht J, Fleckenstein B, Tomlinson P, Barrell B (1987) Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J Virol 61:446–453PubMedPubMedCentralCrossRef

43.

Irmiere A, Gibson W (1983) Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118–133PubMedCrossRef

44.

Mersseman V, Besold K, Reddehase MJ, Wolfrum U, Strand D, Plachter B, Reyda S (2008) Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. J Gen Virol 89:369–379PubMedCrossRef

45.

Gilloteaux J, Nassiri MR (2000) Human bone marrow fibroblasts infected by cytomegalovirus: ultrastructural observations. J Submicrosc Cytol Pathol 32:17–45PubMed

46.

Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185:2043–2051PubMedPubMedCentralCrossRef

47.

Loirat D, Lemonnier FA, Michel ML (2000) Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 165:4748–4755PubMedCrossRef

48.

Holtappels R, Pahl-Seibert MF, Thomas D, Reddehase MJ (2000) Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol 74:11495–11503PubMedPubMedCentralCrossRef

49.

Depto AS, Stenberg RM (1989) Regulated expression of the human cytomegalovirus pp65 gene: octamer sequence in the promoter is required for activation by viral gene products. J Virol 63:1232–1238PubMedPubMedCentralCrossRef

50.

Schmolke S, Kern HF, Drescher P, Jahn G, Plachter B (1995) The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 69:5959–5968PubMedPubMedCentralCrossRef

51.

Besold K, Plachter B (2008) Recombinant viruses as tools to study human cytomegalovirus immune evasion. Med Microbiol Immunol (in press)

Title: Refinement of strategies for the development of a human cytomegalovirus dense body vaccine
Authors: Véronique Mersseman
Verena Böhm
Rafaela Holtappels
Petra Deegen
Uwe Wolfrum
Bodo Plachter
Sabine Reyda
Publication date: 01-06-2008
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-008-0085-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Phenotypes of major immediate-early gene mutants of mouse cytomegalovirus

The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence

The history of cytomegalovirus and its diseases

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection

Rhesus CMV: an emerging animal model for human CMV

MHC class I immune evasion in MCMV infection

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page